Sanofi (SNY) Change in Receivables (2019 - 2021)
Sanofi (SNY) posted Change in Receivables of -$149.9 million for Q4 2021, down 2564.53% sequentially from $6.1 million in Q4 2020, and down 2564.53% YoY from $6.1 million in Q4 2020.
Sanofi (SNY) Change in Receivables (2019 - 2021) Analysis & Trends
Sanofi has reported Change in Receivables for 3 years, with the latest figure at -$149.9 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.35 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.37 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.09 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 333.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -149.86 Mn |
| Dec 31, 2021 | -149.86 Mn |
| Dec 31, 2020 | 6.08 Mn |
| Dec 31, 2020 | 6.08 Mn |
| Dec 31, 2019 | -33.54 Mn |
| Dec 31, 2019 | -33.54 Mn |